VBIV vs. CKPT, MNOV, VHAQ, AEON, CELU, GNLX, RLYB, LTRN, LPTX, and RMTI
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include Checkpoint Therapeutics (CKPT), MediciNova (MNOV), Viveon Health Acquisition (VHAQ), AEON Biopharma (AEON), Celularity (CELU), Genelux (GNLX), Rallybio (RLYB), Lantern Pharma (LTRN), Leap Therapeutics (LPTX), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
VBI Vaccines (NASDAQ:VBIV) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.
VBI Vaccines received 329 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 74.29% of users gave VBI Vaccines an outperform vote while only 66.28% of users gave Checkpoint Therapeutics an outperform vote.
VBI Vaccines has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
In the previous week, Checkpoint Therapeutics had 4 more articles in the media than VBI Vaccines. MarketBeat recorded 5 mentions for Checkpoint Therapeutics and 1 mentions for VBI Vaccines. VBI Vaccines' average media sentiment score of 0.00 equaled Checkpoint Therapeutics'average media sentiment score.
Checkpoint Therapeutics has lower revenue, but higher earnings than VBI Vaccines.
Checkpoint Therapeutics has a consensus target price of $22.60, indicating a potential upside of 1,095.77%. Given Checkpoint Therapeutics' higher possible upside, analysts clearly believe Checkpoint Therapeutics is more favorable than VBI Vaccines.
VBI Vaccines has a net margin of -881.79% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat VBI Vaccines' return on equity.
12.3% of VBI Vaccines shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 10.4% of VBI Vaccines shares are held by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
VBI Vaccines and Checkpoint Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
